A randomized controlled study of sacubitril valsartan in combination with dagliflozin in the treatment of heart failure
Objective To explore the efficacy of the combination of sacubitril valsartan and dagliflozin in the treatment of heart failure and the effects on patients'cardiac function and inflammatory factor levels.Methods One hundred and twenty cases of heart failure patients admitted to our hospital from January 2021 to March 2023 were used as study subjects,and were divided into reference group(60 cases)and experimental group(60 cases)based on the random draw method.The reference group was given sacubitril valsartan,and the experimental group was given dagliflozin+sacubitril valsartan.Clinical efficacy,cardiac function(NYHA)classification before and after treatment,left ventricular end-diastolic internal diameter(LVEDD),left ventricular ejection fraction(LVEF),left ventricular end-systolic internal diameter(LVESD),diastolic interventricular septal thickness(IVST),left ventricular posterior wall thickness(LVPWT),left ventricular mass index(LVMI),and intercellular adhesion molecule(ICAM-1)were compared between the two groups,hypersensitive C-reactive protein(Hs-CRP),nuclear factor-κB(NF-κB),interleukin 33(IL-33),and tumor necrosis factor(TNF-α)levels.Results The total clinical effective rate of the experimental group after treatment was 96.67％higher than that of the reference group,which was 86.67％,and the difference was statistically significant(P＜0.05).After treatment,the levels of cardiac function indexes LVESD and LVEDD were significantly decreased,while the levels of LVEF were significantly increased in the two groups,and the improvement of experimental group was more significant,the difference was statistically significant(P＜0.05).The improvement of NYHA grade in experimental group was greater than that in reference group after treatment,and the difference was statistically significant(P＜0.05).After treatment,the levels of cardiac function indicators LVESD and LVEDD in both groups decreased significantly,and the experimental group had lower levels,the level of LVEF increased significantly and the experimental group had higher levels,and the differences were statistically significant(P＜0.05).After treatment,the levels of serum inflammatory factors IL-33,Hs-CRP,TNF-α and ICAM-1 in experimental groups were reduced more than those in the control group,with statistical significance(P＜0.05).Conclusions Sakobattriovalsartan+Dagliazine is effective in the treatment of heart failure,which can effectively improve cardiac function and ventricular remodeling related indicators,inhibit inflammation in vivo,and contribute to the recovery of the disease.
NETL
NSTL
万方数据
